Pfizer (PFE) chairman and CEO Albert Bourla joins Julie Hyman on Market Domination to talk more about the pharmaceutical ...

What Pfizer’s recent performance tells you right now Pfizer (PFE) has drawn fresh attention after a period in which the share ...

One of the latest voices weighing in is Jason Gerberry of Bank of America, who reiterated a Hold (Neutral) stance on Pfizer on February 4, 2026, setting a price objective of $27.00. This target sits ...

If you are wondering whether Pfizer's current share price still reflects its long term potential, this article will help you ...

Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend offer upside. Click for this PFE update.

Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.

Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...

Geoff Meacham, Citi Research head of U.S. pharmaceuticals and biotechnology, joins 'Squawk Box' to break down the quarterly ...

New weight loss drug by Pfizer shows promising results in trial - Pfizer acquired the drug’s developer following a bidding ...

The stock price of BridgeBio plunged 15% Thursday as Pfizer’s reported decision to withdraw a tafamidis patent in the European Union triggered fears of earlier generic entry in the blockbuster ...

Global pharmaceutical company Pfizer (NYSE:PFE) announced in Q4 CY2025, but sales fell by 1.2% year on year to $17.56 billion ...